NZ332426A - Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds - Google Patents

Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds

Info

Publication number
NZ332426A
NZ332426A NZ332426A NZ33242697A NZ332426A NZ 332426 A NZ332426 A NZ 332426A NZ 332426 A NZ332426 A NZ 332426A NZ 33242697 A NZ33242697 A NZ 33242697A NZ 332426 A NZ332426 A NZ 332426A
Authority
NZ
New Zealand
Prior art keywords
ciliary
infertility
utp
related compounds
treating diseases
Prior art date
Application number
NZ332426A
Other languages
English (en)
Inventor
Karla M Jacobus
Ben R Yerxa
William Pendergast
Richard C Boucher
Janet L Rideout
David J Drutz
Michael K James
Monroe Jackson Stutts
Cara A Geary
Eduardo R Lazarowski
Original Assignee
Univ North Carolina
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Inspire Pharmaceuticals Inc filed Critical Univ North Carolina
Publication of NZ332426A publication Critical patent/NZ332426A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • External Artificial Organs (AREA)
NZ332426A 1996-03-27 1997-03-27 Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds NZ332426A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62491496A 1996-03-27 1996-03-27
PCT/US1997/005101 WO1997035591A2 (en) 1996-03-27 1997-03-27 Method of treating ciliary dyskinesia with uridine triphosphates and related compounds

Publications (1)

Publication Number Publication Date
NZ332426A true NZ332426A (en) 2000-09-29

Family

ID=24503854

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ332426A NZ332426A (en) 1996-03-27 1997-03-27 Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds

Country Status (9)

Country Link
EP (1) EP0889728B1 (enExample)
JP (1) JP4271730B2 (enExample)
CN (1) CN1229114C (enExample)
AT (1) ATE335492T1 (enExample)
AU (1) AU727314B2 (enExample)
CA (1) CA2250188C (enExample)
DE (1) DE69736468T2 (enExample)
NZ (1) NZ332426A (enExample)
WO (1) WO1997035591A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6696425B2 (en) 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6921755B2 (en) 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
CA2295515C (en) * 1997-07-25 2006-03-14 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
US6420331B1 (en) 1998-06-10 2002-07-16 Procter & Gamble Company Detergent compositions comprising a mannanase and a bleach system
ATE222920T1 (de) * 1998-10-02 2002-09-15 Yamasa Corp Ein kristall von diuridine tetraphosphat oder ein solches salz und verfahren zu seiner herstellung, verfahren und herstellung der vorgenannten zusammensetzung
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
AR034635A1 (es) 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
AU2002317053B2 (en) 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
KR20050043761A (ko) 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
BR0215102A (pt) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
CA2557354C (en) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
MX2007015949A (es) 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
IT1395255B1 (it) * 2009-07-09 2012-09-05 Mastelli S R L Composizione per il trattamento di infertilita' maschile
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CN102198264B (zh) * 2010-03-23 2013-10-09 中国科学院上海生命科学研究院 大鼠附睾特异抗菌肽β-防御素15及其用途
JP5806287B2 (ja) 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
JP5922111B2 (ja) * 2010-06-23 2016-05-24 ピーツー−サイエンス・エペイエス 充血剤注入と同時に血圧測定を行う診断目的の動脈用複合カテーテル
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1297862A1 (ru) * 1980-07-03 1987-03-23 Институт цитологии и генетики СО АН СССР Средства дл лечени пигментной дегенерации сетчатки
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
WO1995010287A1 (en) * 1993-10-15 1995-04-20 Wisconsin Alumni Research Foundation Substituted purine nucleoside analogs and method for treating endotoxin shock
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds

Also Published As

Publication number Publication date
DE69736468D1 (de) 2006-09-21
CA2250188C (en) 2008-12-09
EP0889728B1 (en) 2006-08-09
CN1229114C (zh) 2005-11-30
CN1233181A (zh) 1999-10-27
EP0889728A2 (en) 1999-01-13
WO1997035591A3 (en) 1998-01-22
AU2594897A (en) 1997-10-17
JP4271730B2 (ja) 2009-06-03
AU727314B2 (en) 2000-12-07
JP2000507557A (ja) 2000-06-20
ATE335492T1 (de) 2006-09-15
CA2250188A1 (en) 1997-10-02
WO1997035591B1 (en) 2001-04-26
DE69736468T2 (de) 2007-03-29
WO1997035591A2 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
WO1997035591B1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
PH23867A (en) Method of treating parkinson's disease using indolone derivatives
TW371660B (en) Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections
DK1123094T3 (da) Terapeutiske præparater (II)
MX9709637A (es) Dinucleotidos utiles para el tratamiento de enfermedades pulmonares.
EP0962225A3 (en) Use of phentolamine for the manufacture of a medicament for the treatment of erectile dysfunction
HU213677B (en) Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
MX9306049A (es) Dinucleotido de nicotinamida-ademina y fosfato de dinucleotido de nicotinamida-adenina como farmacos para tratar la enfermedad de alzheimer.
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
HUT63058A (en) Process for producing pharmaceutical compositions for treating osteoporosis, comprising pharmaceutically applicable alkalinizing potassium salt
EA200000686A1 (ru) Препараты левозимендана, предназначенные для введения через слизистую оболочку
HUP9900945A2 (hu) Nukleozidanalógok herpes simplex vírus fertőzések kombinációs terápiájában
US4044122A (en) Method of treating herpes virus hominis infections
MX2026001523A (es) Carfilzomib diluido para su uso en el tratamiento del mieloma multiple
CA2167044A1 (en) Oral administration of effective amounts of forms of hyaluronic acid
Veraldi et al. Treatment of epidermolysis bullosa acquisita with cyclosporine and prednisone
RU98103823A (ru) Способ изменения свертывающей и противосвертывающей систем организма
UA30361A (uk) Спосіб лікування глікозидної інтоксикації
MY110769A (en) Controlled release oxycodone compositions.
UA23364A (uk) Спосіб лікування гострого ендометриту
UA38388A (uk) Спосіб лікування епідемічного паротиту
UA37346A (uk) Спосіб імунокорекції при лікуванні загострень хронічних обструктивних захворювань легенів
UA30912A (uk) Спосіб терапії хворих на хронічний обструктивний бронхіт